EP4713364A1 - Anticorps à domaine unique modifiés - Google Patents

Anticorps à domaine unique modifiés

Info

Publication number
EP4713364A1
EP4713364A1 EP24734313.0A EP24734313A EP4713364A1 EP 4713364 A1 EP4713364 A1 EP 4713364A1 EP 24734313 A EP24734313 A EP 24734313A EP 4713364 A1 EP4713364 A1 EP 4713364A1
Authority
EP
European Patent Office
Prior art keywords
seq
domain antibody
amino acid
ala
vai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24734313.0A
Other languages
German (de)
English (en)
Inventor
Ferdinand Huber
Laura PREISS
Annegrit SEIFRIED
Tobias STUWE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Odyssey Therapeutics Inc
Original Assignee
Odyssey Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odyssey Therapeutics Inc filed Critical Odyssey Therapeutics Inc
Publication of EP4713364A1 publication Critical patent/EP4713364A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps à domaine unique comprenant une ou plusieurs modifications, par exemple, au niveau de l'extrémité carboxy-terminale (C-terminus), qui peuvent réduire la liaison par des anticorps anti-médicament à l'extrémité carboxy-terminale des anticorps à domaine unique par comparaison avec un anticorps à domaine unique non modifié. L'invention concerne également des protéines de fusion et des conjugués comprenant les anticorps à domaine unique, des polynucléotides et des vecteurs recombinants codant pour les anticorps à domaine unique, des compositions et des kits les comprenant, ainsi que des cellules hôtes et des procédés de préparation des anticorps à domaine unique.
EP24734313.0A 2023-05-17 2024-05-16 Anticorps à domaine unique modifiés Pending EP4713364A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363467208P 2023-05-17 2023-05-17
PCT/US2024/029687 WO2024238790A1 (fr) 2023-05-17 2024-05-16 Anticorps à domaine unique modifiés

Publications (1)

Publication Number Publication Date
EP4713364A1 true EP4713364A1 (fr) 2026-03-25

Family

ID=91585506

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24734313.0A Pending EP4713364A1 (fr) 2023-05-17 2024-05-16 Anticorps à domaine unique modifiés

Country Status (10)

Country Link
EP (1) EP4713364A1 (fr)
KR (1) KR20260011734A (fr)
CN (1) CN121511255A (fr)
AR (1) AR132699A1 (fr)
AU (1) AU2024273077A1 (fr)
CO (1) CO2025017440A2 (fr)
IL (1) IL324541A (fr)
MX (1) MX2025013732A (fr)
TW (1) TW202448951A (fr)
WO (1) WO2024238790A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025217240A1 (fr) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-tnfr2 et leurs utilisations
WO2025255558A2 (fr) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-lymphopoïétine stromale thymique (tslp) et leurs utilisations
WO2025255435A2 (fr) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène dirigées contre l'albumine sérique et leurs utilisations
WO2026006809A1 (fr) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Molécules multispécifiques se liant à tnfr2 et cd25 et leurs utilisations
WO2026006708A2 (fr) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-cd25 et leurs utilisations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
EP1391213A1 (fr) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
WO2004041863A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique diriges contre un interferon gamma et leurs utilisations
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
US20100323905A1 (en) * 2005-09-23 2010-12-23 Academisch Ziekenhuis Leiden Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates
WO2008020079A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
EP2225277A4 (fr) 2007-11-27 2012-03-14 Viventia Biotech Inc Anticorps dirigés contre un épitope associé au cancer de variant de nfkbib et ses utilisations
EP2285833B1 (fr) 2008-05-16 2014-12-17 Ablynx N.V. Séquences d'acides aminés dirigées contre cxcr4 et autres gpcr et composés renfermant ces dernières
WO2011003622A1 (fr) 2009-07-10 2011-01-13 Ablynx N.V. Procédé pour la production de domaines variables
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (fr) 2011-06-23 2019-09-11 Ablynx NV Protéines se liant à la sérumalbumine
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP3066120B1 (fr) 2013-11-04 2018-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps à domaine unique synthétique
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
EP4707303A2 (fr) 2014-05-16 2026-03-11 Ablynx NV Domaines variables d'immunoglobuline améliorés
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
AU2016214317B2 (en) 2015-02-05 2022-01-13 Ablynx N.V. Nanobody dimers linked via C-terminally engineered cysteins
EP3271391A1 (fr) 2015-03-20 2018-01-24 Ablynx N.V. Domaines variables uniques d'immunoglobuline glycosylés
LT3374392T (lt) 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
JP7219220B2 (ja) 2017-01-17 2023-02-07 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
IL267897B2 (en) 2017-01-17 2025-02-01 Ablynx Nv Improved serum albumin binders
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions

Also Published As

Publication number Publication date
KR20260011734A (ko) 2026-01-23
IL324541A (en) 2026-01-01
CN121511255A (zh) 2026-02-10
CO2025017440A2 (es) 2026-03-16
MX2025013732A (es) 2025-12-01
AU2024273077A1 (en) 2025-11-13
TW202448951A (zh) 2024-12-16
AR132699A1 (es) 2025-07-23
WO2024238790A1 (fr) 2024-11-21

Similar Documents

Publication Publication Date Title
US20240141042A1 (en) MULTISPECIFIC NKp46 BINDING PROTEINS
CN113480656B (zh) 抗ror1抗体
AU2016284871B2 (en) Multispecific NK engager proteins
AU2024273077A1 (en) Modified single-domain antibodies
JP2021184714A (ja) 多重特異性抗体のスクリーニング方法
AU2016383475A1 (en) Variable regions for NKp46 binding proteins
JP6792552B2 (ja) Ｃｃｒ６と結合する抗体およびその使用
KR20160099087A (ko) 이중특이성 her2 항체 및 사용 방법
JP6946184B2 (ja) 抗ｐｄｇｆ−ｂ抗体及び使用法
US20200165354A1 (en) Novel Anti-PCSK9 Antibodies
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
JP2021119788A (ja) 多重特異的結合タンパク質
US20240190990A1 (en) Anti-cea antibodies and methods of use
US11111313B2 (en) Anti-PCSK9 antibodies
WO2023046071A1 (fr) Anticorps anti-klb et leurs utilisations
WO2025255435A2 (fr) Protéines de liaison à l'antigène dirigées contre l'albumine sérique et leurs utilisations
WO2024140925A1 (fr) Anticorps anti-b7h3 et méthodes d'utilisation
WO2025255558A2 (fr) Protéines de liaison à l'antigène anti-lymphopoïétine stromale thymique (tslp) et leurs utilisations
WO2026008055A1 (fr) Anticorps anti-kit et son utilisation pharmaceutique
TW202607017A (zh) 抗血清白蛋白之抗原結合蛋白及其用途
KR20250135302A (ko) 항-cmet 항체 및 사용 방법
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
WO2026056998A1 (fr) Molécule de liaison au gipr et utilisation médicale
KR20250160360A (ko) 항-b7h3 항체 및 사용 방법

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR